Physician profile
Albert Begas
NPI 1245288315
$3,209.78
in general payments reported to CMS, 2019-2025
33 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,061 · 2020: $346 · 2021: $63.48 · 2022: $221 · 2023: $30.82 · 2024: $193 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490 · Education: $28.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.20 |
| Education | $28.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $422.08 | 2019-2025 | Rybrevant |
| Genentech USA, INC. | $377.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $287.93 | 2019-2024 | Enhertu |
| Novocure Gmbh | $200.00 | 2022 | |
| Lilly USA, LLC | $195.48 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $186.83 | 2019-2020 | |
| Genzyme Corporation | $176.64 | 2019-2025 | |
| Daiichi Sankyo INC. | $171.65 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $148.34 | 2019-2025 | Keytruda, Lynparza |
| Pfizer INC. | $136.28 | 2019-2025 | |
| Incyte Corporation | $82.40 | 2019-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $78.33 | 2019-2020 | |
| Seagen INC. | $76.29 | 2019-2020 | |
| Dova Pharmaceuticals | $56.13 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $53.53 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.21 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $49.82 | 2019 | |
| Gilead Sciences, INC. | $48.20 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $40.60 | 2019 | |
| Puma Biotechnology, INC. | $38.96 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $38.63 | 2019 | |
| Celgene Corporation | $37.90 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.99 | 2019 | |
| Kyowa Kirin, INC. | $30.74 | 2019 | |
| Eisai INC. | $27.63 | 2019 | |
| Tempus Ai, INC | $27.24 | 2024 | Xt Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2024 | |
| Agios Pharmaceuticals, INC. | $23.96 | 2019 | |
| Foundation Medicine, INC. | $22.97 | 2019 | |
| Beigene USA, INC. | $19.40 | 2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $15.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Begas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.